UPDATE 2-Teva ratchets in pricing on new benchmark bond
Teva Pharmaceutical looked likely to price its new six-part benchmark bond on Monday with negative concessions after generating a US$70bn book within hours of the announcement. That allowed leads to tighten initial price thoughts 25bp-35bp at guidance, as investors piled into one of the most highly anticipated trades in recent weeks.
from Biotech News
0 Comments